🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨Polygenenic Risk Score for #prostatecancer Screening🚨 📰NEJM 🔑Of patients w/ a PRS>90th %-tile 1⃣ 43% of those w/ PSA<3 had csPCa (≥GG2) 2⃣ 15% of those w/ a negative MRI had csPCa 🔗shorturl.at/iDhOP UroToday.com Renal & Urology News Urology Times GU Cast | Urology podcast! Prostate Cancer Foundation

🚨AR signaling and lncRNA🚨 📰Just published in Science Advances 👉Qi Cao's lab NM Urology show lncRNA PRCAT71 plays a role in stabilizing AR mRNA in #prostatecancer progression 🙏Thankful to be able to play a small role in this remarkable work 🔗shorturl.at/6tg3z

THIS 👇🏼 is what we do it all for!! Cancer research and oncology. It’s all so people like Tony can spend beautiful days with loved ones and loved ones can enjoy the company of people like Tony. 👏🏻👏🏻❤️ PCF Science ASCO ASTRO ESMO - Eur. Oncology ESTRO European Association of Urology (EAU) Amer. Urol. Assn.

🚨Can the transcriptome reveal therapeutic vulnerabilities in localized #prostatecancer?🚨 👉Check out our analysis of >140k tumor samples in European Urology Oncology 🔗shorturl.at/k0J3H

🚨Recruiting U.S. clinicians who manage patients w/ advanced #prostatecancer (e.g., med onc, rad onc, urology, APPs, RD's) for a 1h anonymous virtual interview about nutrition & lifestyle counseling ($40 gift card) -see flyer for more details & contact info. Please help share!

At PCF, we advocate for early and regular prostate cancer screenings. In the wake of former President Biden’s diagnosis, Phillip Koo, MD spoke with the The Washington Post about this philosophy and why we believe that early screening and detection is critical. bit.ly/3H1RoqZ

Very high inter-reader variability is the achilles heel of #prostateMRI What if #prostateMRI could be like a lab test that gives a quantitative value indicating risk of #ProstateCancer? New 📜 Journal of Urology 🧵1/x Amer. Urol. Assn. European Association of Urology (EAU) UroToday.com PCF Science

Howard Soule PCF Science CDMRP NIH National Cancer Institute GE HealthCare Blue Earth Diagnostics Cortechs.ai Quibim 11/x Also excited about newly funded projects!! PCF Science: MRI vs whole-mount histopathology annotated with pathology AI AIRA MATRIX Prostate Cancer UK: fast, enhanced MRI for screening (eg, TRANSFORM). Led by Shonit Punwani Hashim U. Ahmed Tristan Barrett Sean Woolen MD MS Matt Cooperberg

Stunning research from Edmond Kwan on ctDNA in theranostics: 🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy ⚠️PTEN alterations linked to worse outcomes on cabazitaxel 🧪ATM defects tied to favorable PSMA-617 results 🩻PET quantitative

On the eve of #ASCO25, I am delighted to share results from the correlative analyses of the ANZUP phase II TheraP study, now published in Nature Medicine. Massive effort supported by dedicated co-investigators, coordinators, patients & families from 11 study sites across

Congrats #MichaelOng SOUMYAJIT ROY for oral Ab#5002 ASCO #ASCO25👉bit.ly/43NyyfY👉Real-world IRONMAN registry of mHSPC #prostatecancer (n=1288 pts)👉PSA<0.02 after 6-12 mo of Rx had best prognosis (3-yr OS 92.7%)👇Dan George OncoAlert UroToday.com PCF Science

Updated data from #PSMA monitoring study in #BCR #ProstateCancer ASCO #ASCO25 Stop by & see our poster on Monday morning You can see what happens to this pt at 6 months 10+ LNs How would you have managed this case? Trial continues to accrue National Cancer Institute clinicaltrials.gov/study/NCT05588…

Just in from ASCO #ASCO25 👉📢 Finally a T-cell engager in #prostatecancer mCRPC with minimal CRS syndrome (only grade 1, all outpatient dosing) and promising efficacy👇 Congrats #drbaldini Mark Stein and team Journal of Clinical Oncology OncoAlert UroToday.com PCF Science

#VIOLET Study of Terbium-161 (Tb-161) Beta/Auger therapy ASCO #ASCO25 First prospective trial of Terbium-161 in any tumour type 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣 Very few side effects: 1 grade 3

Great discussions @asco #ProstateCancer posters #ASCO25 #PSMA+ #BCR is an indolent process & pts do NOT require urgent therapy in most cases We should be ⚠️ cautious about over-treatment 🔗shorturl.at/NtxdF Trial continues to accrue National Cancer Institute clinicaltrials.gov/study/NCT05588…

Breaking News: Darolutamide is now FDA-approved for mHSPC. It’s used with standard hormone therapy as part of combination treatment—the gold standard for mHSPC. Learn why this matters: pcf.org/the-new-standa…

Prof. Mary-Claire King has been named the 2025 Princess of Asturias Award laureate for science — amazing recognition. Her work on the BRCA1/2 genes led to transforming cancer care, including for men with #ProstateCancer fpa.es/en/princess-of… PCF Science CRIS contra el cáncer

We are hiring a 👩‍🔬 Research Assistant 👨‍🔬 to work on cutting-edge dietary interventions to potentiate DNA damaging therapies in prostate cancer. Come working with us at the @CUSM_MUHC McGill Dept of Surg McGill University! Please share: bit.ly/43V72fs Society for Basic Urologic Research | SBUR PCF Science

Michael Jung kicking off the PCF Science Coffey-Holden #ProstateCancer Academy discussing drug discovery His work to make enzalutamide has certainly made an impact!! 👏🏻👏🏻

#PCFAcademy PCF Science Day 2 session on Cell Death… uff.. each layer of understanding peels back to reveal deeper complexities.. the more I learn, I realize how little I really know 🫣